BR112012016673A2 - método de tratamento. - Google Patents

método de tratamento.

Info

Publication number
BR112012016673A2
BR112012016673A2 BR112012016673A BR112012016673A BR112012016673A2 BR 112012016673 A2 BR112012016673 A2 BR 112012016673A2 BR 112012016673 A BR112012016673 A BR 112012016673A BR 112012016673 A BR112012016673 A BR 112012016673A BR 112012016673 A2 BR112012016673 A2 BR 112012016673A2
Authority
BR
Brazil
Prior art keywords
treatment method
hydrates
administration
patient
directed
Prior art date
Application number
BR112012016673A
Other languages
English (en)
Inventor
B Suttle Albert
King Andrew
M Mclaughlin Megan
Damian-Iordache Valeriu
Original Assignee
Glaxo Wellcome Mfg Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Mfg Pte Ltd filed Critical Glaxo Wellcome Mfg Pte Ltd
Publication of BR112012016673A2 publication Critical patent/BR112012016673A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

método de tratamento. a presente invenção é direcionada a métodos de tratar desordens de angiogênese ocular ou vazamento vascular em um paciente por administração de inibidor adequado, incluindo pazopanib ou sais farmaceuticamente aceitáveis ou hidratos do mesmo.
BR112012016673A 2010-01-06 2011-01-05 método de tratamento. BR112012016673A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29274710P 2010-01-06 2010-01-06
PCT/US2011/020231 WO2011085007A1 (en) 2010-01-06 2011-01-05 Treatment method

Publications (1)

Publication Number Publication Date
BR112012016673A2 true BR112012016673A2 (pt) 2018-06-05

Family

ID=44305773

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012016673A BR112012016673A2 (pt) 2010-01-06 2011-01-05 método de tratamento.

Country Status (20)

Country Link
US (1) US20130012531A1 (pt)
EP (1) EP2521550A4 (pt)
JP (1) JP2013516472A (pt)
KR (1) KR20120125244A (pt)
CN (1) CN102781450A (pt)
AU (1) AU2011203706A1 (pt)
BR (1) BR112012016673A2 (pt)
CA (1) CA2786328A1 (pt)
CL (1) CL2012001852A1 (pt)
CO (1) CO6561789A2 (pt)
DO (1) DOP2012000174A (pt)
EA (1) EA201290603A1 (pt)
IL (1) IL220594A0 (pt)
MA (1) MA33991B1 (pt)
MX (1) MX2012007875A (pt)
PE (1) PE20121523A1 (pt)
SG (1) SG181826A1 (pt)
TW (1) TW201201808A (pt)
UY (1) UY33164A (pt)
WO (1) WO2011085007A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
TW201206908A (en) * 2010-05-05 2012-02-16 Glaxo Wellcome Mfg Pte Ltd Pharmaceutical compositions and methods of making same
AU2011329656B2 (en) 2010-11-19 2017-01-05 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
ES2656292T3 (es) * 2012-05-01 2018-02-26 Translatum Medicus Inc. Métodos de tratamiento y diagnóstico de enfermedades oculares que causan ceguera
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US11136625B2 (en) 2013-08-28 2021-10-05 Crown Bioscience, Inc. (Taicang) Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
AU2015301054B2 (en) 2014-08-08 2020-05-14 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
MX2017015838A (es) * 2015-06-06 2018-08-15 Cloudbreak Therapeutics Llc Composiciones y metodos para tratar pterigion.
US10323349B2 (en) * 2015-09-25 2019-06-18 Kyoudojyutaku Co., Ltd. Washing system
MX2018014868A (es) 2016-06-02 2019-09-13 Cloudbreak Therapeutics Llc Composiciones y metodos de uso de nintedanib para mejorar el exito de la cirugia del glaucoma.
CA3144861A1 (en) 2019-06-25 2020-12-30 Translatum Medicus, Inc. Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1343782T1 (sl) * 2000-12-21 2009-10-31 Smithkline Beecham Corp Pirimidinamini kot modulatorji angiogeneze
DK1968594T3 (da) * 2005-11-29 2010-12-13 Glaxosmithkline Llc Behandling af okulære neovaskulære lidelser, såsom makulær degeneration, striae angioides og makulært ødem
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US8334239B2 (en) * 2007-07-10 2012-12-18 The Board Of Regents Of The University Of Texas System High affinity VEGF-receptor antagonists
US20090325959A1 (en) * 2008-06-26 2009-12-31 Vittitow Jason L Method for treating ophthalmic diseases using rho kinase inhibitor compounds
KR20120049267A (ko) * 2009-07-16 2012-05-16 글락소 웰컴 매뉴팩쳐링 피티이 엘티디 치료 방법

Also Published As

Publication number Publication date
MX2012007875A (es) 2012-08-03
CN102781450A (zh) 2012-11-14
CO6561789A2 (es) 2012-11-15
EA201290603A1 (ru) 2013-03-29
EP2521550A1 (en) 2012-11-14
MA33991B1 (fr) 2013-02-01
WO2011085007A1 (en) 2011-07-14
EP2521550A4 (en) 2013-07-03
KR20120125244A (ko) 2012-11-14
JP2013516472A (ja) 2013-05-13
PE20121523A1 (es) 2012-12-12
UY33164A (es) 2011-08-31
SG181826A1 (en) 2012-07-30
TW201201808A (en) 2012-01-16
CA2786328A1 (en) 2011-07-14
CL2012001852A1 (es) 2012-11-30
DOP2012000174A (es) 2012-12-15
IL220594A0 (en) 2012-08-30
US20130012531A1 (en) 2013-01-10
AU2011203706A1 (en) 2012-07-12

Similar Documents

Publication Publication Date Title
BR112012016673A2 (pt) método de tratamento.
EA201391108A1 (ru) Лечение липодистрофии
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
PH12015501920B1 (en) USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kd RELATED DISORDERS
PH12016502355A1 (en) Pharmaceutical composition
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201190337A1 (ru) Способ лечения
SG195257A1 (en) Anti-thrombotic compounds
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
MX2014011520A (es) Administracion de eritoran o sales farmaceuticamente aceptables del mismo para tratar infecciones para ortomixovirus.
PH12015501211A1 (en) Use of pidotimod to treat atopic dermatitis
EA201491836A1 (ru) Способы лечения рака с использованием ингибитора pi3k и ингибитора mek
MX2014000870A (es) Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina.
GB201107576D0 (en) Novel compounds and methods for use in medicine
UA55818U (ru) Способ лечения хронических заболеваний роговицы
UA56440U (ru) Способ лечения бактериального хронического одонтогенного остеомиелита челюсти
NZ623275A (en) Treatment of ocular disease
MX2013006527A (es) Derivados de arilsulfonamida para la prevencion o el tratamiento de los trastornos oftalmologicos especificos.
UA68841U (ru) Способ хирургического лечения варикоцеле
MX2014005414A (es) Derivados de 2-carboxamida-cicloamino-urea para su uso en el tratamiento de las enfermedades dependientes del factor de crecimiento endotelial vascular (vegf).
UA74055U (ru) Способ хирургического лечения рефрактерных форм глаукомы
UA72157U (ru) Способ лечения начальных форм сосудистых заболеваний головного мозга
UA67427U (ru) Способ лечения фиброзно-кавернозных форм органного туберкулеза
BR112014012817A2 (pt) composições farmacêuticas compreendendo 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetra-hidro-quinolina para neuroproteção retinal

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2475 DE 12-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.